Skip to main content

Relias Media has upgraded our site!

Please bear with us as we work through some issues in order to provide you with a better experience.

Thank you for your patience.

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

In this issue: Results from a Phase 3 study of dabigatran, intensive lipid-lowering in CVD, H1N1 vaccine dosing and efficacy, and FDA Actions.

Pharmacology Watch: Dabigatran: An Oral Direct Thrombin Inhibitor